Ginsenoside RK3 inhibits glioblastoma by modulating macrophage M2 polarization via the PPARG/CCL2 axis
Phytomedicine · 2025
DOI: 10.1016/j.phymed.2024.156271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2025. Verfasst von Haiying Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110042 China. Hauptthemen laut MEDLINE: Glioblastoma, Ginsenosides, PPAR gamma, Macrophages. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Glioblastoma is recognized as the most aggressive form of intracranial tumor, presenting significant challenges in treatment. Recent emphasis has been placed on the potential of traditional Chinese medicine (TCM) as an adjuvant treatment for cancer. METHODS: We employed a series of assays-including CCK8, EdU, Transwell, and neurosphere formation-to evaluate the impact of ginsenoside RK3 on the phenotype of GBM. The modulation of macrophage M2 polarization by ginsenoside RK3 was assessed through flow cytometry, immunohistochemistry, and Western blot analysis. Furthermore, we utilized sequencing analysis and network pharmacology to identify potential therapeutic targets. RESULTS: Our findings reveal that ginsenoside RK3 not only inhibits the phenotype of glioblastoma cells but also suppresses tumor progression in vivo while attenuating macrophage M2 polarization within the tumor immune microenvironment. Notably, ginsenoside RK3 down-regulates PPARG expression in tumor cells, leading to decreased secretion of CCL2, which subsequently diminishes macrophage M2 polarization. Additionally, we demonstrated that combining ginsenoside RK3 with temozolomide significantly enhances the inhibition of glioblastoma's malignant characteristics and progression. CONCLUSIONS: This study innovatively highlights the dual mechanism of ginsenoside RK3 in glioblastoma treatment: it impedes tumor progression by modulating the PPARG/CCL2 pathway and enhances the efficacy of temozolomide. Our research underscores the promising role of herbal medicine in the management of glioblastoma, paving the way for novel therapeutic strategies that integrate traditional approaches with conventional treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110042 China.
- Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001 China.
- Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110001 China.
- Liaoning Maternal and Child Health Hospital, No. 240 Shayang Road, Shenyang 110005, China. Electronic address: syluogang@sina.com.
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, Liaoning 116600, China. Electronic address: doudeqiang724@gmail.com.
Zitieren
APA
Zhang, H., Hu, J., Zhao, X., Zheng, B., Han, Y., Luo, G., & Dou, D. (2025). Ginsenoside RK3 inhibits glioblastoma by modulating macrophage M2 polarization via the PPARG/CCL2 axis. Phytomedicine. https://doi.org/10.1016/j.phymed.2024.156271
Vancouver
Zhang H, Hu J, Zhao X, Zheng B, Han Y, Luo G, et al. Ginsenoside RK3 inhibits glioblastoma by modulating macrophage M2 polarization via the PPARG/CCL2 axis. Phytomedicine. 2025. doi:10.1016/j.phymed.2024.156271
BibTeX
@article{Zhang2025,
author = {Zhang, Haiying and Hu, Jinpeng and Zhao, Xiang and Zheng, Bohao and Han, Ying and Luo, Gang and Dou, Deqiang},
title = {Ginsenoside RK3 inhibits glioblastoma by modulating macrophage M2 polarization via the PPARG/CCL2 axis},
journal = {Phytomedicine},
year = {2025},
doi = {10.1016/j.phymed.2024.156271}
}
EUVIMED